Squamous Cell Cancer of The Lung with Synchronous Renal Cell Carcinoma

Renal cell cancer metastases without evidence of a primary tumor are extremely rare. These variants are usually showed as a spontaneous description of single clinical cases. Aim.This contribution is a clinical follow-up of synchronous renal cell cancer metastases of unknown primary site. Results.A 52-year-old patient U. with a history of increased blood pressure, up to 170/100 mmHg for the last 5 years, who had undergone many instrumental examinations, including ultrasound examination, because of this disease. The computed tomography of the abdomen showed a 4975 mm heterogeneous tumor in the right adrenal gland in October 2017. The combined positron emission and X-ray computed tomography showed a 795441 mm mass in the right adrenal gland, associated with elevated fluorodeoxyglucose metabolic activity SUVmax 7.25. Focal accumulation of the radiopharmaceutical SUVmax 4.31 in a 171124 mm mass was detected in the space of bifurcation in the mediastinum. The lytic lesion (1015 mm) was found in right superior L3 articular process. The patient underwent retroperitoneoscopic adrenalectomy and thoracoscopic removal of mediastinal tumor in November 2017 because of the oligometastatic nature of the process. The histological study identified clear-cell carcinoma with areas of papillary structure in the right adrenal gland. The immunohistochemical study showed carcinoma cells intensively expressing CD10, and some other cells RCC. The immune phenotype of the tumor was identified as clear-cell renal cell carcinoma. The immunohistological and immunohistochemical analysis reviled the metastases of the same variant of renal cell carcinoma in one of 9 lymph nodes. The patient was treated with pazopanib. The primary renal tumor was not detected during the dynamic observation, including the application of annual combined positron emission and X-ray computed tomography. The patient is alive without disease progression with a follow-up of 32 months. Conclusion.Metastases of clear-cell renal cell carcinoma, including adrenal gland, without evidence of a primary site are extremely rare. The main method of treatment is a combination of surgery and targeted therapy, providing long-term local control of the course of the disease.

Download Full-text

Nephrectomy Followed by Interferon Alfa-2b Compared With Interferon Alfa-2b Alone for Metastatic Renal Cell Cancer

50 Studies Every Urologist Should Know ◽

10.1093/med/9780190655341.003.0020 ◽

2021 ◽

pp. 113-118

Author(s):

Christopher Weight

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell Cancer ◽

Renal Cell ◽

Performance Status ◽

Cell Cancer ◽

Interferon Alfa ◽

Cytoreductive Nephrectomy

This chapter summarizes the findings of a landmark trial of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma performed in the interferon era. All enrolled patients had a good performance status. It found overall survival extended by about 3 months in the cytoreductive-nephrectomy-plus-interferon arm versus the interferon-only arm.

Download Full-text

An Unusual Case of Gastrointestinal Bleeding in Metastatic Renal Cell Carcinoma

Case Reports in Oncology ◽

10.1159/000507982 ◽

2020 ◽

Vol 13 (2) ◽

pp. 738-741

Author(s):

Niamh Peters ◽

Clara Lightner ◽

John McCaffrey

Keyword(s):

Renal Cell Carcinoma ◽

Gastrointestinal Bleeding ◽

Cell Carcinoma ◽

Renal Cell ◽

Unusual Case ◽

Upper Gastrointestinal Bleeding ◽

Cell Cancer ◽

Metastatic Spread ◽

Lung Lymph ◽

Upper Gastrointestinal

Approximately 340 patients are diagnosed with renal cell cancer (RCC) in Ireland each year. Metastatic spread to the lung, lymph nodes and bones is common. Metastatic spread to the gastrointestinal tract, including the small bowel, is a rare phenomenon. Therapeutic advances have led to an improved overall survival in RCC and, as a result, unusual sites of metastatic spread are becoming more common. We present the case of a 68-year-old gentleman presenting with upper gastrointestinal bleeding as a result of metastases to the duodenum from renal cell carcinoma.

Download Full-text

The renal cell cancer database Sweden (RCCBaSe) – a new register-based resource for renal cell carcinoma research

Scandinavian Journal of Urology ◽

10.1080/21681805.2020.1766561 ◽

2020 ◽

Vol 54 (3) ◽

pp. 235-240

Author(s):

Anna Landberg ◽

Per Lindblad ◽

Ulrika Harmenberg ◽

Sven Lundstam ◽

Börje Ljungberg ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer

Download Full-text

Medical Treatment of Advanced Renal Cell Carcinoma

Urologia Journal ◽

10.1177/039156039205900614 ◽

1992 ◽

Vol 59 (6) ◽

pp. 54-56

Author(s):

M. Giusto ◽

F. Tuccia ◽

D. Da Corte ◽

C. Puccetti

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Cell Cancer ◽

Interleukin 2 ◽

Response Rates ◽

Advanced Renal Cell Carcinoma ◽

Innovative Strategies ◽

Recombinant Interleukin 2 ◽

History Of

Therapy for disseminated renal cell carcinoma is a major problem, as it's almost completely resistant to standard therapeutic approaches such as chemotherapy or radiotherapy. The search for innovative strategies has led to new concepts based on the assumption that cellular or soluble mediators of the immune system can be rendered cytotoxic or cytostatic for renal cell cancer. With partial response rates of ca. 100% and very promising global response rates, biotherapies are in progress. A number of clinical trials have been perfomed employing systemic administration of interferon (rIFN-) alone or in combination with cytostatic agents, human recombinant interleukin-2 (rlL-2), and, more recently, immunomodulatory agents such as lymphokine-activated killer (LAK) cells: these substances have been demonstrated to be a treatment of choice for advanced renal cell carcinoma, even if they seem unable to modify the natural history of the disease.

Download Full-text

Significance of Chromosome 9p Status in Renal Cell Carcinoma: A Systematic Review and Quality of the Reported Studies

BioMed Research International ◽

10.1155/2014/521380 ◽

2014 ◽

Vol 2014 ◽

pp. 1-11 ◽

Cited By ~ 4

Author(s):

Ismail El-Mokadem ◽

John Fitzpatrick ◽

Bhavan Rai ◽

J. Cunningham ◽

Norman Pratt ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clinical Decision Making ◽

Cell Cancer ◽

Prognostic Significance ◽

Clinical Applicability ◽

Genetic Techniques

Defining the prognosis of renal cell carcinoma (RCC) using genetic tests is an evolving area. The prognostic significance of 9p status in RCC, although described in the literature, remains underutilised in clinical practice. The study explored the causes of this translational gap. A systematic review on the significance of 9p status in RCC was performed to assess its clinical applicability and impact on clinical decision-making. Medline, Embase, and other electronic searches were made for studies reporting on 9p status in RCC. We collected data on: genetic techniques, pathological parameters, clinical outcomes, and completeness of follow-up assessment. Eleven studies reporting on 1,431 patients using different genetic techniques were included. The most commonly used genetic technique for the assessment of 9p status in RCC was fluorescence in situ hybridization. Combined genomic hybridisation (CGH), microsatellite analysis, karyotyping, and sequencing were other reported techniques. Various thresholds and cut-off values were used for the diagnosis of 9p deletion in different studies. Standardization, interobserver agreement, and consensus on the interpretation of test remained poor. The studies lacked validation and had high risk of bias and poor clinical applicability as assessed by two independent reviewers using a modified quality assessment tool. Further protocol driven studies with standardised methodology including use of appropriate positive and negative controls, assessment of interobserver variations, and evidenced based follow-up protocols are needed to clarify the role of 9p status in predicting oncological outcomes in renal cell cancer.

Download Full-text

The role of the immunohistochemical marker p40 in the differential diagnosis of adenocarcinoma and nonkeratinizing squamous cell cancer of the lung

Arkhiv patologii ◽

10.17116/patol20208205150 ◽

2020 ◽

Vol 82 (5) ◽

pp. 50

Author(s):

E.M. Olyushina ◽

M.M. Byakhova ◽

L.E. Zavalishina ◽

Yu.Yu. Andreeva ◽

A.B. Semenova ◽

...

Keyword(s):

Differential Diagnosis ◽

Squamous Cell ◽

Squamous Cell Cancer ◽

Cell Cancer ◽

Immunohistochemical Marker ◽

Cancer Of The Lung

Download Full-text

CpG-island methylation of GATA-family members GATA3 and GATA5 in renal cell carcinoma and association with clinicopathological parameters and progression-free survival.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.5_suppl.370 ◽

2012 ◽

Vol 30 (5_suppl) ◽

pp. 370-370

Author(s):

Inga Peters ◽

Kai Gebauer ◽

Faranaz Atschekzei ◽

Joerg Hennenlotter ◽

Mario W. Kramer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Cpg Island ◽

Cell Cancer ◽

Family Members ◽

Progression Free Survival ◽

Clinicopathological Parameters ◽

Free Survival ◽

Gata Family

370 Background: Transcriptional inactivation and CGI methylation of GATA3 and −5 has been reported to be involved in mammary carcinoma, pancreatic cancer, colorectal and gastric carcinogenesis. A recent study demonstrated that a loss of GATA-3 expression due to partially methylation silencing in several renal cell carcinoma (RCC) patients. We quantitatively investigated GATA3 and −5 CGI methylation in RCC and analyzed its association with clinical characteristics as well as progression free survival of patients. Methods: Methylation data were obtained from a quantitative methylation-specific polymerase chain reaction assay (QMSP) for both genes. We investigated 108 RCC and 77 paired tissue samples as well as six RCC cell lines. Statistical analyses were carried out using the paired t-test for matched tumor (TU) and adjacent normal (adN) samples, logistic regression for comparisons of independent samples and cox regression for survival analysis. Results: In paired samples we found a significant higher methylation in TU compared to adN for GATA3 (P=0.007) and for GATA5 (P=3.6*10−9) for all RCCs. GATA5 showed also strong correlations between methylation and status of metastasis (P=0.05) and advanced (pT≥3 and/or N+, M+) tumor samples compared to localized (pT≤2, N0, M0) tumors (P=4.7*10−9). A decreased progression free survival in cox proportional hazard model analysis could be demonstrated for patients with a high GATA5 methylation (P=0.0006, HR=6.5) and a trend could also be seen for GATA3 methylated patients (P=0.06). Conclusions: GATA3 and −5 were identified to demonstrate tumor-specific CGI hypermethylation in renal cell cancer patients. The association of GATA5 CGI methylation with metastasis, advanced disease and progression free survival of patients indicates that epigenetic alterations of both genes are involved in renal cell carcinogenesis. GATA5 methylation could serve as a biomarker for tumor progression. Further prospective and functional investigations are necessary to clarify whether CGI methylation of GATA family members can provide independent information for future clinical management of patients with RCC.

Download Full-text

Malignant ascites as a manifestation of advanced papillary renal cell cancer (pRCC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.7_suppl.465 ◽

2015 ◽

Vol 33 (7_suppl) ◽

pp. 465-465 ◽

Cited By ~ 2

Author(s):

Julia C. Friend ◽

Daniel Su ◽

Rashmi Thimmapuram ◽

James Peterson ◽

Geri Hawks ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Disease ◽

Renal Cell ◽

Clinical Characteristics ◽

Clear Cell ◽

Cell Cancer ◽

Malignant Ascites ◽

Urologic Oncology ◽

True Incidence

465 Background: Peritoneal carcinomatosis and ascites are frequent and clinically challenging complications associated with several malignancies such as ovarian cancer. Although ascites is rarely reported in patients with advanced renal cell carcinoma (RCC), its true incidence, particularly in non-clear cell variants, remains poorly defined. Here, we describe the incidence of and clinical characteristics associated with ascites in patients with pRCC. Methods: Patients with metastatic renal cell carcinoma (RCC) seen at the NCI Urologic Oncology Branch were identified in a review of our clinical database. The incidence of radiologically and/or cytologically evident ascites, relevant associated clinical characteristics, and survival were evaluated as was the incidence of ascites in a contemporaneous clear cell RCC (ccRCC) cohort. Results: 241 patients with metastatic RCC were seen between 2002 and 2014, including 109 with pRCC and 125 with ccRCC. Seventeen patients with metastatic pRCC (17/109,15.5%) had evidence of malignant ascites, while only 1/125 pts (0.8%) with ccRCC developed this complication. Median age of PRCC patients with ascites was 45.8 years (range: 26.1 to 76.6 years). Ascites was seen in both patients with type 1 (15.6%, 10/64) and those with type 2 pRCC (15.5%, 7/45). Median time to development of ascites from initial diagnosis of metastatic disease was 16 months (95% CI 7-23 months). Median survival from diagnosis of metastatic disease was 25 months (95% CI 13-41months) in patients with ascites, compared to 20 (95% CI 14-31 months) in those without this complication. (p = 0.59). Conclusions: To our knowledge, this is the largest series evaluating the incidence of and outcome associated with ascites in RCC. Although rare in ccRCC, malignant ascites is a fairly common manifestation of metastatic pRCC. In our cohort, patients with ascites appeared to have outcomes comparable to patients with metastatic pRCC without ascites.

Download Full-text